Iterum Therapeutics Reports First Quarter 2021 Financial Results
May 14, 2021 07:00 ET
|
Iterum Therapeutics plc
FDA Review of NDA for Oral Sulopenem Continues; Current Prescription Drug User Fee Act (PDUFA) date of July 25, 2021 Cash Runway into First Half of 2023 Company to host conference call today at...
Iterum Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on May 14, 2021
May 07, 2021 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, May 07, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 08:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, April 06, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors
March 16, 2021 07:30 ET
|
Iterum Therapeutics plc
Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
March 12, 2021 07:00 ET
|
Iterum Therapeutics plc
--NDA for Oral Sulopenem has PDUFA date of July 25, 2021-- --Cash Runway into First Half of 2023— --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 12,...
Iterum Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 12, 2021
March 05, 2021 17:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, March 05, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present in Upcoming Investor Conferences
February 19, 2021 17:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares
February 10, 2021 18:40 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules
February 09, 2021 23:58 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics plc Increases Previously Announced Bought Deal Public Offering of Ordinary Shares to $40.0 Million
February 03, 2021 23:35 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...